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Abstract
Background: The aim of this survey was to determine the prevalence of and factors associated with Helicobacter
pylori (H. pylori) colonization in HIV-infected, highly active antiretroviral therapy-naïve Ugandan children aged 0-12
years.
Methods: In a hospital-based survey, 236 HIV-infected children were tested for H. pylori colonization using a faecal
antigen test. A standardized interview with socio-demographic information and medical history was used to assess
risk factors. A cluster of differentiation 4 (CD4) cell percentage was prevalent in most children.
Results: The overall prevalence of H. pylori in the HIV-infected children was 22.5%. Age-specific prevalence was as
follows: up to one year, 14.7%; 1-3 years, 30.9%; and 3-12 years, 20.7%. HIV-infected children who were more
seriously affected by their disease (low CD4 cell percentage or WHO clinical stage II-IV) were less likely to be
colonized with H. pylori. There was a trend for a lower prevalence of H. pylori in children who had taken antibiotics
for the preceding two weeks (21.6%) than in those who had not taken antibiotics (35.7%). There was no statistically
significant difference in prevalence by gender, housing, congested living, education of the female caretaker,
drinking water or toilet facilities.
Conclusions: HIV-infected, HAART-naïve Ugandan children had a lower prevalence of H. pylori colonization
compared with apparently healthy Ugandan children (44.3%). Children with a low CD4 cell percentage and an
advanced clinical stage of HIV had an even lower risk of H. pylori colonization. Treatment with antibiotics due to
co-morbidity with infectious diseases is a possible explanation for the relatively low prevalence.
Background
Sub-Saharan Africa accounts for 67% of all people living
HIV, and carries the highest burden of the global HIV
epidemic [1]. In Uganda, it has been estimated that 1.1
million people, including 120,000 children, were living
with HIV in 2008 [2]. The gastrointestinal tract is the
largest immunological site of the body and HIV infec-
tion profoundly impacts on gut function [3,4]. HIV-
infected children are affected by numerous gastrointest-
inal problems [5].
Helicobacter pylori, which can cause chronic gastritis, is
associated with recurrent peptic ulcers and gastric cancer
[6,7]. It is one of the most common causes of bacterial
infection in man [8,9]. It was first isolated and cultured
from the antrum of patients with gastritis by Warren and
Marshall in 1983 [10]. H. pylori colonization is thought
to be acquired early in life. Early colonization in children
living in poor socio-economic conditions has been
demonstrated, and several studies have shown a high pre-
valence of H. pylori among people in low-income coun-
tries [11-15]. The overall prevalence was 44.3% in our
recently published study on apparently healthy, urban
Ugandan children [15].
Published data on H. pylori infections in HIV-infected
persons are mainly based on adults [16] and are from
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non-epidemic areas [17], and many studies have under-
taken serological tests [18] or have been conducted on
persons referred for gastrointestinal complaints [19].
These studies report diverging estimates of the preva-
lence of H. pylori [20]. To the best of our knowledge,
there seem to be no studies on the prevalence of
H. pylori in HIV-infected children living in sub-Saharan
Africa. In a study designed to describe the findings in
HIV-infected South African children who underwent
gastroscopy, rates of H. pylori colonization were
reported, and only one out of 26 children was colonized
[21].
There are currently four distinct methodologies for H.
pylori detection and/or identification: (1) 13Urea breath
test [22,23]; (2) gastroscopy with biopsies and culture; (3)
serology tests; and (4) antigen tests. The 13Urea breath
test or invasive methods, such as gastroscopy with biop-
sies and/or urease tests, used to be the “gold standard”
for detection of H. pylori. A 13Urea breath test is time
consuming and personnel dependent. A gastroscopy
should be performed when a child presents clinical symp-
toms for diagnosis and is not justified for mere identifica-
tion of H. pylori. Serological tests are available, but have
several drawbacks: (1) they do not discriminate between
current and past infections; (2) they show low specificity
in children and are thus of little use [24,25]; and (3) no
data is available about the specificity and sensitivity of
serological tests in HIV-infected individuals with immu-
nodeficiency and altered antibody production.
The faecal monoclonal antigen test has a high sensitiv-
ity, specificity and accuracy in children: 91-100, 84-96
and 94-96%, respectively [26-28]. In a review on the
incidence of H. pylori in HIV-infected patients [20], the
use of the faecal antigen test is recommended for
further studies due to its higher specificity in this popu-
lation. It can be used on humans of all age groups, gives
a rapid result without being invasive, and is not affected
by acid-regulating medicines.
Our main objective was to determine the prevalence
and factors associated with H. pylori colonization in
HIV-infected, highly active antiretroviral therapy-
(HAART-) naïve children aged 0-12 years in urban
Kampala, Uganda.
Methods
Study site and data collection
The survey was conducted from February to October 2008
at the Department of Paediatrics and Child Health,
Mulago National Referral Hospital, Kampala, a govern-
ment-run hospital. It assumes the role of the local hospital
for the people living in the area of Mulago Hill and, at the
same time, the role of a national referral hospital for
Uganda. Participants were enrolled from the general
paediatric medical wards, the acute care unit, the ward for
malnutrition and the paediatric infectious diseases clinic.
We decided in advance on an enrolment period of nine
months. The data was collected by a doctor with experi-
ence in data collection and in paediatric HIV pre- and
post-test counselling, as well as diagnosis and treatment of
paediatric HIV. She was fluent in the local languages and
English. GN and EH trained her in stool sampling, inter-
view technique and ethical issues. GN was available for
consultation if necessary. Children admitted during the
enrolment period to the wards we have mentioned were
invited to participate in the study if they were HIV
infected, but HAART naïve, aged 0-12 years, and only
after receiving informed consent from their caretaker. The
ward matrons were asked to identify the eligible children
and their caretakers. All those so identified children and
caretakers were invited to participate.
The HIV status of the children was known before
enrolment from routine testing as part of the medical
service at the Department of Paediatrics and Child
Health. HIV testing followed the Ugandan national
guidelines [29] that closely follow the World Health
Organization (WHO) guidelines. Children over 18
months of age were tested using a rapid blood test with
a sensitivity rate > 98%. To confirm positive test results,
a second test with a different antigenic specificity was
used. If there was discordance between the two tests, an
ELISA test (tie-breaker) was used to make a final diag-
nosis. For children under 18 months of age, a polymer-
ase change reaction test was used to give a reliable HIV
diagnosis.
Study population
The study population (Figure 1) consisted of 246 HIV-
infected, HAART-naïve children aged up to 12 years.
Only 4.1% of the eligible children (10/246) were not
included in the final analysis as a result of: no H. pylori
test performed (six); failure to produce a stool sample in
three days (three); and providing an incomplete ques-
tionnaire (one). In 219 of the 236 participants, CD4 cell
counts expressed as percentages were available. We clas-
sified CD4 cell percentage as high or low with limits
defined by age: (1) for children < 12 months, high if
CD4 cell percentage was > 25%: (2) for 12-36 months,
high if CD4 cell percentage was > 20%; and (3) for ≥36
months, high if CD4 cell percentage was > 15%. The
limits chosen were concurrent with those recommended
for starting HAART according to the WHO guidelines
available at the time of the study [30]. All children were
clinically categorized using the WHO staging system for
HIV-infected children [31] since it is recommended for
evaluating the need to start up HAART in children
when CD4 cell counts are unavailable [30].
Hestvik et al. Journal of the International AIDS Society 2011, 14:34
http://www.jiasociety.org/content/14/1/34
Page 2 of 9
H. pylori stool antigen test
Stool samples requested from each participating child
were collected in airtight containers at the time of the
encounter, the end of the day, or the following morning.
They were transported from the ward to the laboratory
twice daily and stored in a +4°C fridge for a maximum of
24 hours before analysis by the H. pylori stool antigen test,
HpSA®ImmunoCardSTAT, as per the manufacturer’s
instructions. A standard positive control test was per-
formed after every 20 tests, all of them being verified as
positive. The HpSA®ImmunoCardSTAT is a rapid lateral-
flow immunoassay that utilizes a monoclonal anti-H.
pylori antibody as the capture and detector antibody.
Approximately 100 μl of stool was transferred into the
sample diluent vial and vortexed for 15 seconds. Four
drops of the specimen were applied to the test and the
result was read after five minutes. The results were
reported as positive or negative based on the manufac-
turer’s cut-off values.
Statistical analysis
Data from the questionnaires, the results of the faecal
antigen test and CD4 cell percentages were doubly
entered using EpiData version 3.1 (http://www.epidata.
dk). Data quality was ensured through careful selection
and training of research assistants, supervision, and field
editing by use of the “check” module at data entry com-
bined with double data entry and validation. The
“checks” at data entry were limits set by the study team
to ensure that it was not possible to enter obviously
wrong information. For example, a child can measure
only between 48 cm and 180 cm (it is not possible to
enter other data), and many answers can only be “yes”
or “no”.
After entering all data twice in separate files, the two
separate data files were validated by comparison and any
non-matching data were checked manually against the ori-
ginal paper form. The data were exported to SPSS version
17.0 for statistical analysis. To explore the prevalence of
H. pylori and its association with other factors, bivariate
logistic regression and multiple logistic regression were
performed. Adjustments were made in the multiple logis-
tic regression analysis for age, sex, CD4 cell percentage,
clinical WHO staging, type of housing, number of people
in the same household, education of the mother or female
caretaker, sources of drinking water, toilet type (pit
Department of Paediatrics, 
Mulago National Referral Hospital,
Kampala
246 HIV-infected, HAART-naïve 
children aged 0-12 years
236 HIV-infected, HAART-naïve 
children aged 0-12 years
10 children excluded:  
• not performed H.pylori test (6)
• failed to provide stools (3)
• incomplete data (1)
219 HIV-infected, HAART-naïve 
children aged 0-12 years
with CD4 cell percentage available
17 children:
• CD4 cell percentage not available
Figure 1 Study profile.
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latrine), sharing of the toilet with other families, reported
abdominal pain, wealth index, and drugs taken.
Due to the lack of known CD4 cell percentages in 17
participants, the multiple logistic regression analysis
involved only 219 participants. The confidence interval
(CI) reported was set at 95%, and the significance level
was set at 0.05. To explore the socio-economic status of
the participants, principal component analysis (PCA) was
used. Twelve questions encompassed socio-economic
status (composed of assets in the household, sources of
power available for the family, standard of housing for
the child, and if the family were farmers or owned their
own land and/or house), and we carried out PCA for
these questions. The model captured ~79% of our results;
the Kaiser-Meyer-Oklin value was 0.79, exceeding the
recommended value of 0.6, and the Barletts Test of
Sphericity reached statistical significance. PCA revealed
the presence of three components with Eigen values
exceeding 1. The first principal component was used as
our wealth index, explaining 30.5% of the variance. The
wealth index was ranked and categorized into three
tertiles (1 - poorest, 2 - poorer, 3 - least poor) that were
equally distributed.
Ethics
Ethical approval was obtained from Makerere University,
Faculty of Medicine, Research and Ethics Committee in
Uganda, and the Regional Committee for Medical and
Health Research Ethics, West-Norway (REK-VEST) in
Norway. The data collectors were trained in ethical issues
prior to the survey. Oral and written information about
the study was given to the caretakers either in English or
the local language. Informed consent was obtained from
all the caretakers of the participants in the study. If the
doctor found the medical history of a participating child
suspect of gastritis and the child tested positive for
H. pylori, the child was given triple therapy of amoxicil-
lin/claritromycin/omeprazole for one week. All children
participating in the study were independently managed
for their medical needs by the doctor in charge of the
ward.
Results
The mean age (± SD) of the 236 participants who com-
pleted the study was 2.9 (2.8) years; for girls 2.8 (2.8)
years and boys 3.1 (2.8) years. The youngest enrolled
child was 1.5 months. There were 19 children younger
than six months enrolled. The genders were equally
represented in the survey: 121 (51.3%) girls and 115
(48.7%) boys.
The overall prevalence of H. pylori antigen in the 236
children was 22.5 % (Table 1).
Age-specific prevalence was: (1) for up to one year,
14.7%: (2) for 1-3 years, 30.9%; and (3) for 3-12 years,
20.7%. The difference in prevalence between the young-
est children and the group aged 1-3 years was signifi-
cant, also after adjusting for the other factors in the
multiple logistic regression analysis (Table 2). The lower
prevalence after the age of three years was not statisti-
cally significant. There was no difference in colonization
rates of H. pylori by gender.
CD4 cell percentages were available for 219 partici-
pants. A low CD4 cell percentage was significantly asso-
ciated with a lower H. pylori colonization rate, with an
odds ratio (OR) and 95% confidence interval (OR ± 95%
CI) of 0.33 (0.2-0.7), (Table 2). Participants with WHO
stage II-VI had lower H. pylori colonization (20.8%) com-
pared with those with WHO stage I (37.5%) (Table 3).
The difference was not statistically significant (OR = 0.4;
95% CI 0.2-1.1) (Table 2).
In the unadjusted analysis, the H. pylori colonization
was higher among the poorest participants than among
the other participants (OR ± 95% CI) of 2.2 (1.0-4.8),
but the difference was not statistically significant after
adjusting for the other factors in the analysis (Table 2).
There was no statistically significant difference in
colonization rate in participants who had taken any kind
of drugs or antibiotics within the last three months or
two weeks before the survey assessment (Table 2).
There was a lower colonization rate in children who
had had antibiotics in the last three months (20.6 versus
27.9%) and in the last two weeks (21.6 versus 35.7%),
but the difference was not statistically significant. Pro-
phylaxis with cotrimoxazole was common (69.9%), but
there was no different in the colonization rate between
participants with or without prophylaxis.
There was no statistically significant difference in
H. pylori prevalence by type of housing, congested liv-
ing, education of female caretaker, drinking water
sources, toilet facilities or reported abdominal pain
(Table 2).
Discussion
In this large survey of HIV-infected children in an Afri-
can urban setting, we identified a lower colonization
rate of H. pylori in HIV-infected children compared
with healthy children in the same area of Kampala,
Uganda [15]. HIV-infected children more seriously
affected by their disease (low CD4 cell percentage or
WHO stage II-IV) were less likely to be colonized with
H. pylori.
This is the first survey describing the prevalence of
H. pylori colonization among HIV-infected, HAART-
naïve Ugandan children. This is a novel survey in an
epidemic area of HIV with focus on the prevalence of
H. pylori in HAART-naïve children. Only two previous
studies have provided data on prevalence of H. pylori in
HIV-infected children [32,33], neither of them from
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Table 1 Prevalence of Helicobacter pylori in Ugandan HIV-infected children by age groups
Age categories Total number N H. pylori positive n H. pylori prevalence % (95% CI)
0 < 1 year 68 10 14.7 (6-23)
1 < 3 years 81 25 30.9 (21-41)
3 < 6 years 53 12 22.6 (11-34)
6 < 9 years 22 4 18.2 (1-36)
9 < 12 years 12 2 16.7 (8-41)
Total 236 53 22.5 (17-28)
Table 2 Helicobacter pylori colonization in HIV infected, treatment naïve children and associated factors
Number
N
HP positive n
(%)
Unadjusted odds ratio (95%
CI)
p
value
Adjusted odds ratio1 (95%
CI)
p
value
Age groups
0 < 1 year 68 10 (14.7) 1 1
1 < 3 years 81 25 (30.9) 2.6 (1.1-5.9) 0.02 2.8 (1.1-6.8) 0.03
3 < 12 years 87 18 (20.7) 1.5 (0.6-3.5) 0.34 1.2 (0.5-3.2) 0.65
Sex
Male 115 22 (19.1) 1 -
Female 121 31 (25.6) 1.5 (0.8-2.7) 0.23
CD4 cell percentage2
High 115 35 (30.4) 1 1
Low 104 13 (12.5) 0.3 (0.2-0.7) 0.002 0.3 (0.1-0.6) 0.001
Who classification
WHO stage I 24 9 (37.5) 1 -
WHO stage II-VI 212 44 (20.8) 0.4 (0.2-1.1) 0.07
Type of housing
Permanent house 105 23 (21.9) 1 -
Semi-permanent house 131 30 (22.9) 1.1 (0.6-2.0) 0.86
Number of people
in same household
2-4 126 28 (22.2) 1 -
≥5 110 25 (22.7) 1.0 (0.6-1.9) 0.93
Education of the
mother/female caretaker
Completed primary 83 21 (25.3) 1 -
school or higher
Incomplete primary
school
153 32 (20.9) 0.8 (0.4-1.5) 0.44
Drinking water
Public tap 138 28 (20.3) 1 -
Unprotected sources 98 25 (25.5) 1.4 (0.7-2.5) 0.34
Type of toilet
Open pit/pit latrine 228 52 (22.8) 1 -
VIP latrine/flush toilet 8 1 (12.5) 0.5 (0.1-4.0) 0.50
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endemic areas for HIV. A Belgian study [32] on 23 HIV-
infected children of central African ethnic origin and
born in Belgium used a serology test to detect H. pylori
colonization. They found none of the tested children to
be colonized compared with 19.2% of children in a con-
trol population.
An Italian study [33], using both serology and 13Urea
breath tests in 45 perinatally HIV-infected children, found
a prevalence of 17.7 and 20.0%, respectively. This was not
different from a control population, but the HIV-infected
and the control patients were both recruited from a socio-
economic background predisposing them to H. pylori
Table 2 Helicobacter pylori colonization in HIV infected, treatment na?ï?ve children and associated factors (Continued)
Sharing of toilet
with other families
No 72 16 (22.2) 1 -
Yes 164 37 (22.6) 1.0 (0.5-2.0) 0.95
Taken drugs last 3
months4
No 40 10 (25.0) 1 -
Yes 196 43 (21.9) 0.8 (0.4-1.9) 0.67
Taken any antibiotics3
last 3 months
No 61 17 (27.9) 1 -
Yes 175 36 (20.6) 0.7 (0.3-1.3) 0.24
Taken any antibiotics
last 2 weeks
No 14 5 (35.7) 1 -
Yes 222 48 (21.6) 0.5 (0.2-1.6) 0.23
Taken deworming
medicine last 6 months
No 125 23 (18.4) 1 -
Yes 111 30 (27.0) 1.6 (0.9-3.0) 0.12
Wealth index
Least poor 78 12 (15.4) 1 -
Poorer 80 19 (23.8) 1.7 (0.8-3.8) 0.19
Poorest 77 22 (28.6) 2.2 (1.0-4.8) 0.05
Reporting abdominal pain
more than 3 times/week
No 224 49 (21.9) 1 -
Yes 12 4 (33.3) 1.8 (0.5-6.2) 0.36
1Adjusted for the 219 participants for whom CD4 percentage were available; adjustment was made for all categories included in the table.
2CD4 cell percentage was available for 219 of the 236 participants
3Last 2 weeks not included in this category
Table 3 Prevalence of Helicobacter pylori in Ugandan HIV-infected children by WHO stage
WHO stage Total number N H. pylori positive n H. pylori prevalence % (95% CI)
Stage I 24 9 37.5 (17-58)
Stage II 44 8 18.2 (6-30)
Stage III 145 32 22.1 (15-29)
Stage VI 23 4 17.4 (1-34)
Total 236 53 22.5 (17-28)
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colonization; many of the children had a caretaker
involved in intravenous drug abuse [33]. In 26 HIV-
infected South African children who underwent gastro-
scopy, the rates of H. pylori colonization were reported,
and only one child was colonized [21]. Our survey had a
large sample size compared with other studies describing
H. pylori prevalence in HIV-infected children [21,32,33].
In this survey, we used an active antigen method to
investigate the colonization of H. pylori. A positive test
is evidence of a current infection and not the possibility
of a previous infection, which could have been the case
had a serological test been used. If a test based on anti-
body detection was used, a participant with severe
immunodeficiency could eventually show a false negative
result due to an inadequate immune response. From
other studies, we know that the antigen test used has
high sensitivity and specificity in non-HIV-infected
populations [26,27], and is recommended for screening
in HIV-infected population [20].
A weakness is that we have no data on the specificity
and sensitivity of this test in HIV-infected, immune-sup-
pressed populations. Another weakness is that the num-
ber of children over six years of age was small compared
with the rest of the study population, increasing the con-
fidence interval of our estimates for H. pylori prevalence
in the older age group. We failed to recruit more children
over six years of age due to the natural history of AIDS
and due to our inclusion criteria being HAART-naïve
children.
In the adjusted multiple regression analysis, we had
only 219 participants as 7.2% of the study population
did not have their CD4 cell percentages measured. This
made analysis more complex, but comparison of the
models with 219 participants and all 236 participants
showed no significant differences in OR with 95% CI or
p values. In the analysis in Table 2, some of the factors
had a much more skewed distribution and the survey
did not have enough power to detect differences in the
prevalence of H. pylori.
We have recently reported the prevalence of H. pylori in
apparently healthy children in Kampala, Uganda [15].
Apparently healthy Ugandan children had an overall pre-
valence of H. pylori of 44.3%; HIV-infected Ugandan chil-
dren had an overall prevalence of H. pylori of 22.5%. The
prevalence in the HIV-infected children was lower in all
age groups compared with apparently healthy children
(Figure 2).
Although there are limitations, the two studies have
similarities. The two study populations have children aged
0-12 years, the gender distribution is similar, the same
antigen test was used in both studies, and both studies
were performed in urban areas. Sanitation conditions did
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Figure 2 Comparison of prevalence of Helicobacter pylori in apparently healthy and HIV-infected Ugandan children by age.
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not differ much between the two populations. The limita-
tions of comparing the two studies are that one group is
community based, receiving home visits, and the present
study is hospital based, and that in the community-based
study, 39% of the participants had taken antibiotics in the
last three months versus 74% in the present study.
We identified a statistically significantly lower coloni-
zation rate of H. pylori in children who had low CD4
cell percentages. A CD4 cell percentage is more accu-
rately used in young children due to the natural decline
in the total lymphocyte count and the CD4 cell count
[34]. To the best of our knowledge, there are no studies
performed in child populations showing differences in
prevalence of H. pylori according to the CD4 cell count.
In adult populations, we find support for our findings:
in a study from Argentina [35], the authors concluded
that HIV-infected patients with H. pylori had a higher
mean CD4 cell count than those without H. pylori; and
a Zambian study [36] showed that HIV-infected adult
patients with CD4 cell counts below 200 cells/mm3
were less likely to have positive H. pylori serologies (OR
0.29; 95% CI 0.09-0.93).
We found that H. pylori colonization was significantly
higher in children aged 1-3 years than in children
younger than one year of age. This is comparable to
data for apparently healthy children from the same
region [15], but it has not been described earlier among
HIV-infected children in this age group. An Italian
study [33] describing colonization of H. pylori by age
only included three children younger than three years
and none younger than one year of age.
We speculate that the colonization rates among the HIV
infected are the same as in apparently healthy children,
but among the HIV-infected children, accidental eradica-
tion is taking place due to the high use of antibiotics in
these children; 74% of the children had taken antibiotics
within the last three months and 95% of the survey partici-
pants were on antibiotics at time of enrolment or had
taken antibiotics within the preceding two weeks.
Hospitalization therapy for bacterial infections, worms
and protozoa are often given simultaneously if infections
are present. These combined therapies can also be effec-
tive against H. pylori and eradicate it in a proportion of
children. The use of antibiotics against opportunistic
infections in HIV-infected populations is the most
hypothesized explanation for lower colonization rates
[19,20,37]. We could only show a trend of lower coloni-
zation among children who had used antibiotics. We
assume that we could not show a significant difference
between those who had used antibiotics and the others
due to the large number of participants who had been
treated with antibiotics in the past compared with those
who had not been treated. The study was not designed
to show those differences.
To use a clinical staging system for AIDS is useful and
recommended when a CD4 cell count is not available,
but it is not recommended for use for initiating HAART
if a CD4 cell count is available [30]. We could not
demonstrate a significant difference relating to the clini-
cal HIV WHO stage and the prevalence of H. pylori, but
there was a trend for lower colonization rates in more
advanced stages (Table 3). We think this is because
many of the criteria used for advanced staging are
chronic or recurrent infection. These infections are trea-
ted with antibiotics, for example, amoxicillin against
upper airway infections; this drug is also recommended
as a part of the triple treatment of H. pylori [38].
There was no significant difference in prevalence by
sex, type of housing, congested living, education of
female caretaker, drinking water sources, toilet facilities,
reported abdominal pain or wealth index. A possible
explanation for the lack of such association, as described
in non-HIV-infected children [11,14,15,39], is that the
impact of the CD4 cell percentage is very strong and
independent of the factors we have mentioned.
Conclusions
HIV-infected, HAART-naïve, urban Ugandan children had
a lower prevalence of H. pylori colonization compared
with apparently healthy Ugandan children. Children with
more advanced HIV (a low CD4 cell percentage and
advanced clinical stage of HIV) had lower rates of coloni-
zation of H. pylori; this might indicate that these children
had more frequently been treated with drugs also effective
against H. pylori. Treatment with antibiotics or other
drugs effective against H. pylori, due to co-morbidity with
infectious diseases, is a likely explanation for the relatively
low prevalence.
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